Free Daily Podcast Summary
The Genetics Podcast: Daily Summaries Delivered
by Sano Genetics
Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago36 min
EP 263: Bringing the first cardiovascular gene editing therapy to patients with Sek Kathiresan of Eli Lilly
This week on The Genetics Podcast, Patrick is joined by Dr. Sek Kathiresan, CEO of Verve Therapeutics and SVP, Head of Obesity Research and Early Development at Eli Lilly. They discuss how protective genetic variants led to the development of a one-time gene editing therapy for heart disease in the face of early doubt, the phase one results for Verve-102, what recent trial failures mean for genetic target validation, and the unmet needs in obesity treatment.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Sek 01:40 Sek’s family history of heart disease and how it motivated him to pursue cardio therapeutics03:29 Sek’s background and research on the genetics of coronary artery disease and protective mutations08:03 Reactions to the Verve launch and the biological, technological, regulatory, and commercial risks11:00 Verve-102 phase one results and the case for lifelong LDL lowering16:14 Why cumulative exposure means lowering LDL earlier and for longer17:53 Recent trial failures in genetically validated targets and what the Lp(a) trial leaves unanswered20:33 Polygenic risk scores and who benefits most from LDL lowering23:36 Sek’s new role at Lilly and the remaining unmet needs in obesity treatment29:06 Whether one-time gene therapy could work for obesity and how GLP-1 drugs drive weight loss30:38 Food intake, energy expenditure, and the search for new obesity mechanisms32:15 Why Lilly is investing so heavily in genetic medicine34:35 Closing remarksFind out moreANGPTL3 study in NEJM (https://pmc.ncbi.nlm.nih.gov/articles/PMC3008575/)Verve-102 study (https://www.nejm.org/doi/10.1056/NEJMoa2601283)
- 2 weeks ago38 min
EP 262: The genetic drivers of hemochromatosis, drug response, and multimorbidity with Luke Pilling of the University of Exeter
This week on The Genetics Podcast, Patrick is joined by Dr. Luke Pilling, Senior Lecturer in Genetic Epidemiology at the University of Exeter. They discuss hemochromatosis and the case for earlier diagnosis, and the genetic drivers of multimorbidity, pharmacogenetics, and drug response.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Luke 01:37 An overview of HFE hemochromatosis and why diagnosis is delayed 04:24 Iron levels and overload risk in heterozygous and compound heterozygous carriers05:51 Aging-related effects seen in homozygotes 06:43 How hemochromatosis is currently diagnosed and detected in the UK09:26 Future screening and case finding, including the Our Future Health cohort11:28 Genetic and environmental factors that shape outcomes in C282Y homozygotes 13:28 The GEMINI project and the genetic drivers of multimorbidity15:56 Drug targets from multimorbidity genetics, including repurposing and opposite effects18:49 Using disease sequences in health records to look for earlier intervention points in multimorbidity21:21 Data gaps limiting multimorbidity research, from primary care records to proteomics23:17 Handling misdiagnosis and clinical code accuracy in health record research24:55 International collaborations and the need for more diverse biobank data26:08 Pharmacogenetics research and how genetic variants shape drug response29:04 Limited clinical examples of pharmacogenetics and lessons from non-responders33:08 Genetics of lifespan and healthy aging, and why geroscience pathways rarely appear in GWAS36:06 Luke’s future research focuses 40:39 Closing remarksFind out more:- Hereditary hemochromatosis study- Multimorbidity study- Pharmacogenetics framework study
- 3 weeks ago36 min
EP 261: Inside the virtual biotech staffed by AI agents with James Zou of Stanford University
This week on The Genetics Podcast, Patrick is joined by Dr. James Zou, Associate Professor of Biomedical Data Science at Stanford University. They discuss the concept of virtual biotechs and how AI agents link single cell data to clinical trial success, Paper to Agent and turning papers into living virtual authors, clinical AI from EchoNet to SleepFM, and the role of academia alongside big AI labs.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to James 01:55 An overview of James’s virtual biotech and its AI scientist agents04:11 How single cell evidence behind drug targets predicts clinical trial success06:33 Behind the scenes of how autonomous the virtual biotech agents are08:06 Missing proprietary trial data as the next gap for the virtual biotech09:44 Scaling the number of collaborating AI agents as a new frontier for drug discovery12:29 How teamwork and structure evolved among the agents 15:53 Behind the idea of Paper to Agent and virtual authors19:01 What converting over 100 papers into agents revealed about reproducibility23:14 The story behind EchoNet, an FDA-cleared AI tool for cardiac ultrasound26:28 Predicting risk for over 100 future diseases from one night of sleep27:40 Transferring SleepFM from sleep labs to consumer wearables28:43 Combining multimodal health data to predict disease30:10 Longitudinal blood proteomics as the biggest data gap for health AI31:18 The role of academia as an open, neutral counterweight to big AI labs32:51 How James’s path from Cambridge math and Harvard machine learning led to biology34:41 Closing remarksFind out moreVirtual biotech paper (https://www.science.org/doi/10.1126/science.aeg6779)Paper2Agent paper (https://www.nature.com/articles/s41586-026-11044-y)
- 4 weeks ago45 min
EP 260: How AI is reshaping genomics, disease prediction, and biosecurity with Jeffrey Barrett of the University of Helsinki
This week on The Genetics Podcast, Patrick is joined by Dr. Jeffrey Barrett, Group Leader at the Ellis Institute Finland and the University of Helsinki. They discuss using AI and federated biobank data to stratify common chronic diseases, how LLMs reading clinical notes in Finland's health registries can reveal treatment response, how AI is changing the way scientists research and train, and what the UK's COVID genome sequencing effort means for biosecurity.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Jeff 02:08 Jeff's research focus for his new lab, including molecular subtyping of common chronic diseases with AI06:18 Barriers to pooling biobank data across research environments for federated AI models11:00 Why Jeff expects larger datasets to make complex models better at predicting disease13:34 The three disease areas Jeff's lab will target first: cardiometabolic, inflammatory and neuropsychiatric19:41 Using LLMs to read clinician notes in Finland's health registries for treatment response24:50 How Jeff uses AI in his research and where humans still need to read and review31:08 Using Claude to understand papers and the gaps in its literature searches32:14 Jeff on AI solving open problems in mathematics and biology, and where researchers fit35:48 Simultaneous discoveries and why lab data generation still needs experts39:01 Jeff's COVID genome sequencing at Sanger and what it means for AI and biosecurity43:16 Closing remarks
- Oct 1, 202638 min
EP 259: A patient community driving awareness and research for Danon disease with Jenny Hsieh of the Danon Foundation
SummaryThis week on The Genetics Podcast, Patrick is joined by Jenny Hsieh, Co-Founder and President of the Danon Foundation. They discuss how Danon disease affects males and females, why it is so often misdiagnosed, the current therapy landscape and research priorities, and how families can make informed decisions about gene therapy trials.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Jenny 01:28 An overview of Danon disease02:34 Sex differences in Danon disease and severe disease in females05:15 Why Danon disease is misdiagnosed and how it may be spotted earlier08:50 Therapy pipeline for Danon and the Foundation's global patient coordination13:46 Origin story of the Danon Foundation18:10 Research priorities and the burden of Danon disease beyond the heart22:39 Raising genetic testing awareness among ophthalmologists and cardiologists for Danon disease25:20 Recognizing broader Danon symptoms and launching the first Danon Awareness Day29:37 Informed consent and trial literacy for families weighing gene therapy33:14 Patient-friendly trial experiences36:19 Ways to support Danon research37:37 Closing remarksFind out moreDanon Foundation
- Sep 24, 202639 min
EP 258: The mutations hiding in healthy tissues with Inigo Martincorena of the Wellcome Sanger Institute
This week on The Genetics Podcast, Patrick is joined by Dr. Inigo Martincorena, Group Leader at the Wellcome Sanger Institute. They discuss the discovery of widespread cancer-driver mutations in normal tissue, the role of somatic mutations in autoimmune disease, new sequencing technologies transforming the field, and the therapeutic potential of targeting these mutations.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Inigo 01:46 How Inigo's eyelid skin study revealed widespread cancer-driver mutations07:14 Findings from a follow-up study on esophageal tissue10:02 How NanoSeq technology scaled somatic mutation research across tissues12:34 The thyroid study linking somatic mutations to autoimmune disease17:07 How escaped B cell clones evolve into polyclonal autoimmune disease20:21 Immune gene mutations occurring in healthy aging lymphocytes21:21 Why driver mutation clones in normal tissue rarely become cancer24:16 Two therapeutic paradigms for targeting somatic mutations in disease28:13 Examples of somatic rescue mutations in the colon, liver, and blood29:20 Why clonal selection only occurs in dividing cell types31:20 The field's remaining blind spots in mobile immune cells and rare samples33:46 How new single-cell sequencing will link genotype to phenotype36:03 What Inigo has learned from collaborating across Sanger's expertise38:09 Closing remarksFind out moreEyelid studyEsophagus study
- Sep 17, 202639 min
EP 257: Managing hereditary cancer risk and medical uncertainty with Marleah Dean Kruzel of the University of South Florida
This week on The Genetics Podcast, Patrick is joined by Dr. Marleah Dean Kruzel, Professor of Communication at the University of South Florida. They discuss her personal path from watching breast cancer move through her family to testing positive for a hereditary mutation herself, the ART framework she developed for managing uncertainty, and the complexities of communicating genetic risk within families.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Marleah01:35 Marleah's family history of breast cancer across four generations02:48 Marleah's childhood living through her mother's five-year cancer battle04:26 Marleah's experience with genetic testing07:19 How a positive test result reshaped Marleah’s PhD research focus08:40 The central challenges of living with a positive test result 10:50 The ART framework for managing hereditary cancer uncertainty15:06 Applying the ART framework to Patrick’s experience with uncertainty and the importance of having a support system 19:53 Common misconceptions in how families communicate genetic risk23:54 The previvor identity and the chronic uncertainty it brings25:40 How Marleah has learned to accept and embrace uncertainty27:57 Balancing logic and emotion in hereditary cancer family planning31:28 How Marleah grounds her research tools in patients' lived experience33:21 How AI is eroding our capacity to sit with uncertainty35:57 Redesigning healthcare for a lifespan of genetic risk information38:10 Closing remarks
- Sep 10, 202640 min
EP 256: Cutting through the AI hype in drug discovery with Dave Hallett of Recursion
This week on The Genetics Podcast, Patrick is joined by Dr. David Hallett, Chief Scientific Officer at Recursion. They discuss the biggest shifts in drug discovery over Dave's three-decade career, where AI is genuinely transforming the field today versus where the hype outruns the reality, and how Recursion's perturbational maps have uncovered and validated a novel neurodegeneration target.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Dave01:57 The biggest shifts in drug discovery over three decades06:39 Where AI is delivering real wins across drug discovery today12:19 How AI-assisted trial simulation reveals which eligibility criteria to relax14:46 The three biggest reasons drug programs fail in the clinic 18:20 How Recursion's perturbational maps uncover new drug targets24:58 A four-step framework for validating a novel drug target28:44 How Recursion balances deep therapeutic focus with partnership breadth30:52 Why AI can't shortcut clinical trials, and what proof of real impact looks like34:57 The skills scientists need most in the AI era, and why trusting AI outputs starts with trusting the data39:52 Closing remarksFind out more:Recursion (https://www.recursion.com/)
Get The Genetics Podcast summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Genetics Unzipped
Explores stories from the world of genetics, from Mendel's experiments to modern genome research.
Extend Podcast with Darshan Shah, MD
Explores science-backed strategies and expert insights to extend healthspan and optimize longevity through actionable health protocols.
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
The BioHub - by Avetix
Conversations with leading biotech experts reveal the strategies and stories driving innovation in the biotechnology industry.
Huberman Lab
Explores neuroscience and science-based tools for understanding and improving brain function, behavior, and health.
LONGEVITY with Nathalie Niddam
Explores science-backed strategies for extending healthspan through nutrition, biohacking, peptides, and emerging longevity research.
Stanford Psychology Podcast
Students interview psychologists about recent research and its real-world applications.
Peak Performance Life Podcast
Covers health, energy, and mental performance optimization through biohacking, nutrition, and lifestyle strategies.
Get Better Faster
Doctors and researchers discuss functional medicine and root-cause approaches to chronic illness and health optimization.
In the Interim...
Explores Bayesian statistics and adaptive clinical trial designs in medical research with insights from industry experts.
ON CRISPR: The Story of Jennifer Doudna with Walter Isaacson
A Nobel-winning biochemist pioneers CRISPR gene editing, sparking scientific breakthroughs, global competition, and ethical debates.
The VPZD Show
Two physicians discuss healthcare, medicine, and policy from a contrarian, middle-ground perspective.
About The Genetics Podcast
Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Genetics Podcast in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Genetics Podcast daily summary?
It's a free AI-powered email that summarizes new episodes of The Genetics Podcast as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Genetics Podcast podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Genetics Podcast product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Sano Genetics.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does The Genetics Podcast release new episodes?
The Genetics Podcast publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Genetics Podcast cover?
The Genetics Podcast covers topics including Science, Natural Sciences, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Genetics Podcast summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.